TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes

Rony Dahan, Moran Tabul, Yuan K. Chou, Roberto Meza-Romero, Shayne Andrew, Adolph J. Ferro, Gregory G. Burrows, Halina Offner, Arthur Vandenbark, Yoram Reiter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Antigen-presenting cell-associated four-domain MHC class II (MHC-II) molecules play a central role in activating autoreactive CD4+ T cells involved in multiple sclerosis (MS) and type 1 diabetes (T1D). In contrast, two-domain MHC-II structures with the same covalently attached self-peptide (recombinant T-cell receptor ligands (RTLs)) can regulate pathogenic CD4+ T cells and reverse clinical signs of experimental autoimmune diseases. RTL1000, which is composed of the β1α1 domains of human leukocyte antigen (HLA)-DR2 linked to the encephalitogenic human myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide, was recently shown to be safe and well tolerated in a phase I clinical trial in MS. To evaluate the opposing biological effects of four- versus two-domain MHC-II structures, we screened phage Fab antibodies (Abs) for the neutralizing activity of RTL1000. Five different TCR-like Abs were identified that could distinguish between the two- versus four-domain MHC-peptide complexes while the cognate TCR was unable to make such a distinction. Moreover, Fab detection of native two-domain HLA-DR structures in human plasma implies that there are naturally occurring regulatory MHC-peptide complexes. These results demonstrate for the first time distinct conformational determinants characteristic of activating versus tolerogenic MHC-peptide complexes involved in human autoimmunity.

Original languageEnglish (US)
Pages (from-to)1465-1479
Number of pages15
JournalEuropean Journal of Immunology
Volume41
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

HLA Antigens
Peptides
Multiple Sclerosis
Antibodies
Peptide T
T-Lymphocytes
Clinical Trials, Phase I
Antigen-Presenting Cells
T-Cell Antigen Receptor
Neutralizing Antibodies
Autoimmunity
Type 1 Diabetes Mellitus
Bacteriophages
Autoimmune Diseases
Ligands
human MOG protein
Protein Domains
myelin oligodendrocyte glycoprotein (35-55)

Keywords

  • Autoimmunity
  • Immune tolerance
  • MHC class II
  • Recombinant antibodies

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes. / Dahan, Rony; Tabul, Moran; Chou, Yuan K.; Meza-Romero, Roberto; Andrew, Shayne; Ferro, Adolph J.; Burrows, Gregory G.; Offner, Halina; Vandenbark, Arthur; Reiter, Yoram.

In: European Journal of Immunology, Vol. 41, No. 5, 05.2011, p. 1465-1479.

Research output: Contribution to journalArticle

Dahan, Rony ; Tabul, Moran ; Chou, Yuan K. ; Meza-Romero, Roberto ; Andrew, Shayne ; Ferro, Adolph J. ; Burrows, Gregory G. ; Offner, Halina ; Vandenbark, Arthur ; Reiter, Yoram. / TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes. In: European Journal of Immunology. 2011 ; Vol. 41, No. 5. pp. 1465-1479.
@article{90509defe5ce45709aa7cb1846f0b60a,
title = "TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes",
abstract = "Antigen-presenting cell-associated four-domain MHC class II (MHC-II) molecules play a central role in activating autoreactive CD4+ T cells involved in multiple sclerosis (MS) and type 1 diabetes (T1D). In contrast, two-domain MHC-II structures with the same covalently attached self-peptide (recombinant T-cell receptor ligands (RTLs)) can regulate pathogenic CD4+ T cells and reverse clinical signs of experimental autoimmune diseases. RTL1000, which is composed of the β1α1 domains of human leukocyte antigen (HLA)-DR2 linked to the encephalitogenic human myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide, was recently shown to be safe and well tolerated in a phase I clinical trial in MS. To evaluate the opposing biological effects of four- versus two-domain MHC-II structures, we screened phage Fab antibodies (Abs) for the neutralizing activity of RTL1000. Five different TCR-like Abs were identified that could distinguish between the two- versus four-domain MHC-peptide complexes while the cognate TCR was unable to make such a distinction. Moreover, Fab detection of native two-domain HLA-DR structures in human plasma implies that there are naturally occurring regulatory MHC-peptide complexes. These results demonstrate for the first time distinct conformational determinants characteristic of activating versus tolerogenic MHC-peptide complexes involved in human autoimmunity.",
keywords = "Autoimmunity, Immune tolerance, MHC class II, Recombinant antibodies",
author = "Rony Dahan and Moran Tabul and Chou, {Yuan K.} and Roberto Meza-Romero and Shayne Andrew and Ferro, {Adolph J.} and Burrows, {Gregory G.} and Halina Offner and Arthur Vandenbark and Yoram Reiter",
year = "2011",
month = "5",
doi = "10.1002/eji.201041241",
language = "English (US)",
volume = "41",
pages = "1465--1479",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes

AU - Dahan, Rony

AU - Tabul, Moran

AU - Chou, Yuan K.

AU - Meza-Romero, Roberto

AU - Andrew, Shayne

AU - Ferro, Adolph J.

AU - Burrows, Gregory G.

AU - Offner, Halina

AU - Vandenbark, Arthur

AU - Reiter, Yoram

PY - 2011/5

Y1 - 2011/5

N2 - Antigen-presenting cell-associated four-domain MHC class II (MHC-II) molecules play a central role in activating autoreactive CD4+ T cells involved in multiple sclerosis (MS) and type 1 diabetes (T1D). In contrast, two-domain MHC-II structures with the same covalently attached self-peptide (recombinant T-cell receptor ligands (RTLs)) can regulate pathogenic CD4+ T cells and reverse clinical signs of experimental autoimmune diseases. RTL1000, which is composed of the β1α1 domains of human leukocyte antigen (HLA)-DR2 linked to the encephalitogenic human myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide, was recently shown to be safe and well tolerated in a phase I clinical trial in MS. To evaluate the opposing biological effects of four- versus two-domain MHC-II structures, we screened phage Fab antibodies (Abs) for the neutralizing activity of RTL1000. Five different TCR-like Abs were identified that could distinguish between the two- versus four-domain MHC-peptide complexes while the cognate TCR was unable to make such a distinction. Moreover, Fab detection of native two-domain HLA-DR structures in human plasma implies that there are naturally occurring regulatory MHC-peptide complexes. These results demonstrate for the first time distinct conformational determinants characteristic of activating versus tolerogenic MHC-peptide complexes involved in human autoimmunity.

AB - Antigen-presenting cell-associated four-domain MHC class II (MHC-II) molecules play a central role in activating autoreactive CD4+ T cells involved in multiple sclerosis (MS) and type 1 diabetes (T1D). In contrast, two-domain MHC-II structures with the same covalently attached self-peptide (recombinant T-cell receptor ligands (RTLs)) can regulate pathogenic CD4+ T cells and reverse clinical signs of experimental autoimmune diseases. RTL1000, which is composed of the β1α1 domains of human leukocyte antigen (HLA)-DR2 linked to the encephalitogenic human myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide, was recently shown to be safe and well tolerated in a phase I clinical trial in MS. To evaluate the opposing biological effects of four- versus two-domain MHC-II structures, we screened phage Fab antibodies (Abs) for the neutralizing activity of RTL1000. Five different TCR-like Abs were identified that could distinguish between the two- versus four-domain MHC-peptide complexes while the cognate TCR was unable to make such a distinction. Moreover, Fab detection of native two-domain HLA-DR structures in human plasma implies that there are naturally occurring regulatory MHC-peptide complexes. These results demonstrate for the first time distinct conformational determinants characteristic of activating versus tolerogenic MHC-peptide complexes involved in human autoimmunity.

KW - Autoimmunity

KW - Immune tolerance

KW - MHC class II

KW - Recombinant antibodies

UR - http://www.scopus.com/inward/record.url?scp=79955137620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955137620&partnerID=8YFLogxK

U2 - 10.1002/eji.201041241

DO - 10.1002/eji.201041241

M3 - Article

VL - 41

SP - 1465

EP - 1479

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 5

ER -